O.I. Kit, E.M. Frantsiyants, L.S. Kozlova, E.V. Verenikina, Yu.A. Pogorelova, N.S. Chugunova, I.S. Tavaryan
Rostov Cancer Research Institute at the Ministry of Health of Russia, Rostov-on-Don
Kozlova L.S. ― Cand. Biol. Sc., Associate Professor, Senior Researcher of the Rostov Cancer Research Institute at the Ministry of Health of Russia
Introduction. Malignant ovarian tumors have no obvious clinical signs that distinguish them from benign ones. Study of fibrinolysis system is important to understand the biological properties of ovarian cancer; it helps to specify some theoretical aspects necessary to develop new approaches to prevent the disease spread and benign tumors malignancy.
Goal ― study of plasmin (P), plasminogen (PG), its activators (uPA and tPA), PAI-1 inhibitor in the ovarian cancer tissue at I-IV stages of development in comparison with benign tumors.
Material and methods. Operating material of 76 patients with serous cystadenocarcinoma (T1N0M0; T2N0M0; T3NxM0; T4Nx-1M0; 51,5±1,7 years), 47 patients with cystadenoma, 48,8±2,7 years, was studied using ELISA method. Morphologically unaltered tissue of the ovaries removed on the occasion of the uterine fibroid in 20 patients, 52,3±1,9 years, was used as the control.
Results. Reduction in the PG content in all the tissues studied, increase in the free P activity with T1N0M0 and T2N0M0, PG and free P depletion with T3NxM0 and T4Nx-1M0; increase in P-α2-antiplasmin (PAP) complex in all the tissues except for T4Nx-1M0 and unaffected ovary with T1N0M0, were established. Increase in uPA-AG and uPA-act in all the tissues studied, with respect to the control; reduction in tPA-AG in all the tissues and increase in tPA-act with T2N0M0 and T3NxM0, were found. PAI-1-AG increased in all the tissues with respect to the control, with T4Nx-1M0 – twice as high as in other tumors. PAI-1-act reduced in all the tissues, except for T3NxM0.
Conclusion. Similarity of PG, PAP, uPA, tPA, PAI-1 changes in malignant and benign ovarian tumors was found. It is assumed that these components can participate in the progression of cystadenocarcinoma and cystadenoma malignancy.
Key words: cystadenoma and ovarian cystadenocarcinoma, fibrinolysis system.